GSK boosts low-carbon inhaler development with PhIII trials, investment in French manufacturing facility
GSK is taking the next steps to develop a low-carbon alternative to its metered dose inhaler (MDI), Ventolin, through beginning Phase III clinical trials next year as well as investing in a manufacturing site in Évreux, France.
Announced ahead of COP28, the UN climate change conference, starting Nov. 30, the pharma giant said it’s looking to cut greenhouse emissions by reducing the carbon footprint of its Ventolin inhalers, used to treat or prevent bronchospasm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.